跳至主要内容
临床试验/NCT05543512
NCT05543512已完成不适用

An Allergen-specific Immune Signature-directed Diet vs Sham Diet for Treatment of Eosinophilic Esophagitis: A Pilot-feasibility Study

University of North Carolina, Chapel Hill1 个研究点 分布在 1 个国家目标入组 68 人开始时间: 2022年10月24日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
68
试验地点
1
主要终点
Post-treatment peak eosinophil count

研究概览

简要总结

This is a randomized, double blind, sham-controlled, pilot/feasibility trial of individualized dietary elimination treatment.

详细描述

Participants will be randomized in a 1:1 fashion to follow an allergen-specific immune signature-directed diet or sham diet during the 8-week treatment period. Blood and biopsies specific to this study will be collected during a baseline endoscopy completed as part of their routine clinical care. Samples will be immediately transported to a lab in which T-cell and immunoglobulin G4 (IgG4) signatures will be analyzed for the full 18 food panel. If randomized to the active intervention, then participants in a blinded fashion will be assigned a diet that removes the foods for which they had a positive threshold result on either the T-cell or IgG4 assay. If randomized to the sham diet, then participants will be provided a sham diet. Sham diets will be developed via selecting a random number of foods from a random list of the potential eliminated foods. The participant, investigators, clinical research coordinators, and study dietician will be blinded to the results of laboratory analysis during the course of the study. The lab, study monitor, or other designee not otherwise involved in the study will be unblinded.

Upon assignment of their diet intervention, participants will meet with a study dietician to discuss their baseline food consumption and assigned diet intervention. After 4 and 8 weeks of diet intervention, they will check-in with the study dietician. In addition, they will monitor their food intake for compliance. At the end of the 8-week treatment period, participants will return for an endoscopy with biopsies and blood draw. Upon completion of the 8-week endoscopy, participation in this study is complete and participants will return to routine care of their condition which may include dietary re-introduction if clinically indicated after completion of the iDIET study.

The primary hypothesis is that participants treated with the immune-signature diet will have significantly lower post-treatment eosinophil counts and dysphagia symptom scores than participants treated with sham diet.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Care Provider, Investigator)

盲法说明

Blinded

入排标准

年龄范围
16 Years 至 80 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • In order to be eligible to participate in this study, an individual must meet all of the following criteria:
  • Age: 16 - 80 years
  • Diagnosis of EoE as per consensus guidelines
  • No prior treatment with, or documented failure of, dietary elimination therapy. Failure is defined as =>15 eos/hpf after a course of the six-food elimination diet (SFED).
  • On stable diet for 4 weeks prior to screening endoscopy and agree to maintain throughout course of participation. Foods eliminated for allergic or other reactions are not exclusionary and may continue to be avoided throughout participation in the study regardless of food trigger results.
  • In addition to meeting the above criteria, to be eligible for randomization an individual must meet all of the following criteria:
  • Active EoE (=>15 eos/hpf) based on clinical biopsies taken during baseline endoscopy
  • Must have at least one positive food on the IgG4 or T cell stimulation assay

排除标准

  • Concomitant eosinophilic gastritis and/or enteritis, confirmed with a prior clinicohistologic diagnosis
  • Use of systemic corticosteroids within 4 weeks of the baseline/qualifying endoscopic exam
  • Previous esophageal resection
  • History of bleeding disorder or esophageal varices
  • Current use of blood thinners such as coumadin, warfarin, heparin, and/or novel anticoagulant agents (requires discontinuation of medication within an appropriate time frame for that specific agent and in accordance with standard clinical practice)
  • Medical instability that precludes safely performing upper endoscopy
  • Inability to read or understand English
  • Pregnancy or breastfeeding
  • Body mass index (BMI) <17

研究组 & 干预措施

Individualized Diet Elimination Therapy

Experimental

Subjects in this arm will be assigned an allergen-specific immune signature-directed diet to follow for 8 weeks

干预措施: Algorithm to diagnose food allergens (Device)

Sham Diet Elimination Therapy

Placebo Comparator

Subjects in this arm will be assigned a sham diet to follow for 8 weeks

干预措施: Sham diet (Other)

结局指标

主要结局

Post-treatment peak eosinophil count

时间窗: 8 weeks

Post-treatment peak eosinophil count (measured in eos/hpf)

Post-treatment Peak Eosinophil Count

时间窗: 8 weeks

Post-treatment peak eosinophil count (measured in eos/hpf)

次要结局

  • Dysphagia symptom score(8 weeks)
  • Endoscopic severity(8 weeks)
  • Percentage of Histologic Responders(8 weeks)
  • Dysphagia Symptom Score(8 weeks)
  • Endoscopic Severity(8 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验